

**Bibliographic Information: WO01/94300**

**Acylphenyl urea derivatives and their use for treatment of type II diabetes.** Defossa, Elisabeth; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Baringhaus, Karl-Heinz. (Aventis Pharma Deutschland G.m.b.H., Germany). PCT Int. Appl. (2001), 55 pp. CODEN: PIXXD2 WO 2001094300 A1 20011213 Designated States W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM. Designated States RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG. Patent written in German. Application: WO 2001-EP6030 20010526. Priority: DE 2000-10028175 20000609; DE 2001-10116768 20010404. CAN 136:37410 AN 2001:904090 CAPLUS

**Patent Family Information**

Patent No.	Kind	Date	Application No.	Date
WO 2001094300	A1	20011213	WO 2001-EP6030	20010526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10116768	A1	20021010	DE 2001-10116768	20010404
AU 2001062318	A5	20011217	AU 2001-62318	20010526
CA 2411082	AA	20021205	CA 2001-2411082	20010526
EP 1294682	A1	20030326	EP 2001-936399	20010526
EP 1294682	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011457	A	20030624	BR 2001-11457	20010526
JP 2003535843	T2	20031202	JP 2002-501817	20010526
EE 200200634	A	20040415	EE 2002-634	20010526
AT 265424	E	20040515	AT 2001-936399	20010526
NZ 523034	A	20040730	NZ 2001-523034	20010526
PT 1294682	T	20040930	PT 2001-936399	20010526
ES 2215902	T3	20041016	ES 2001-1936399	20010526
RU 2271350	C2	20060310	RU 2003-100092	20010526
US 2002151586	A1	20021017	US 2001-875901	20010608
US 6506778	B2	20030114		
ZA 2002009759	A	20030630	ZA 2002-9759	20021202
NO 2002005879	A	20030129	NO 2002-5879	20021206
<u>Priority Application</u>				
DE 2000-10028175	A	20000609		
DE 2001-10116768	A	20010404		
WO 2001-EP6030	W	20010526		

**Abstract**

Title compds. I [A = (un)substituted Ph, naphthyl, etc.; R1, R2 = H, alkyl, alkanoyl, alkoxy carbonyl, etc.; R3, R4, R5, R6 = H, F, Cl, Br, CF3, etc.; X = O, S; R7 = carboxyalkyl, (alkoxy carbonyl)alkyl, carbamoylalkyl, etc.] were prep'd. Thus, trichloro deriv. II was prep'd. in 4 steps starting from N-(3,5-dichloro-4-hydroxyphenyl)acetamide and Et 6-bromohexanoate. At 10  $\mu$ M II showed 87% inhibition of glycogen phosphorylase a in vitro.

